A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
A research peptide arrives as a small white or off-white solid at the bottom of a vial — sometimes a neat disc, sometimes a thin film, sometimes a scattering of powder that looks as though the vial were dropped. All three can be good material: the shape of the cake is a poor guide to its condition.
What matters is what freeze-drying achieved, what it did not, and which clock starts ticking when.
What lyophilisation does
The peptide is dissolved, frozen, and then held under vacuum while the ice sublimes directly to vapour without passing through a liquid phase — primary drying. A second, warmer stage removes water that is adsorbed rather than frozen: secondary drying. What is left is the peptide, any excipients, the counter-ions from purification, and some residual moisture.
The point of the exercise is that water is a reactant. Hydrolysis needs it, deamidation is accelerated by it, and molecular mobility inside the solid scales with it. Remove most of the water and the chemistry that destroys a peptide in solution slows by orders of magnitude.
Two things qualify that. The drying itself is a stress — freezing concentrates the solute, shifts pH as buffer components crystallise out at different rates, and creates a large ice-water interface that can unfold and aggregate a sensitive molecule. The formulation science around this is well developed, and the practical consequences of drying stress and of residual moisture have been reviewed at length (PMID 9279875, PMID 20143256). And a dried solid is not inert. It is a glass in which reactions proceed slowly, and how slowly depends on how much water remains and how far below its glass transition temperature it is kept.
The routes by which a dried peptide degrades
Worth naming, because they are what a storage condition is actually defending against.
Deamidation. Asparagine and glutamine residues convert to aspartate and glutamate through a cyclic intermediate. The mass shifts by about one dalton and the chromatographic behaviour barely changes, which is why this is the degradation most likely to pass an inattentive analysis. Moisture and higher pH both accelerate it.
Oxidation. Methionine, cysteine and tryptophan are the vulnerable residues. Atmospheric oxygen, trace metals and light all contribute. This is the main argument for amber vials, intact seals and headspace that was flushed with inert gas rather than left as air.
Hydrolysis and backbone cleavage. Aspartate-containing sequences are particularly prone to cleavage at the peptide bond, and the rate depends on the neighbouring residue.
Aggregation. Peptides associate at interfaces — air-liquid, ice-liquid, glass. Aggregates are often invisible, usually irreversible, and may still appear as a single peak if they dissociate under chromatographic conditions.
Disulfide scrambling. Any sequence with more than one cysteine can re-pair incorrectly. The mass does not change, so mass spectrometry will not catch it.
Racemisation. Slow, residue-dependent, and mass-silent.
Only some of these appear in a routine purity determination, which is one of the reasons a certificate is a statement about a moment rather than a guarantee about a vial. That argument is set out in what a certificate of analysis establishes, and the detection limits of each method in HPLC and LC-MS in peptide testing.
Storage conditions, and why they differ by state
Laboratory technique for a solid and for a solution — nothing more.
| State | Condition |
|---|---|
| Lyophilised, short term | 2–8 °C, protected from light and moisture |
| Lyophilised, long term | −20 °C, sealed, desiccated |
| Lyophilised, archival | −80 °C |
| In solution | 2–8 °C, protected from light, and treated as short-lived |
Three practical notes on the freezer. A frost-free domestic freezer runs a defrost cycle that warms its contents repeatedly; a manual-defrost or laboratory unit does not. Repeated freeze-thaw is a stress in its own right, which is the entire argument for splitting a solution into single-use aliquots rather than returning to one vial. And a cold vial opened in a warm room condenses atmospheric moisture onto the solid — let it equilibrate to room temperature in its sealed state before the seal is broken.
Note also that a published storage figure belongs to the specific product. Retatrutide's label here reads 2–8 °C where the rest of this catalogue reads −20 °C, and the specification follows the label rather than the house convention.
Once it is in solution, the clock changes
Reconstitution ends the protection that drying bought. Everything above runs faster in water.
Diluent choice matters. Bacteriostatic water contains a small proportion of benzyl alcohol, which suppresses microbial growth but does nothing about chemical degradation; sterile water for injection has no preservative at all. Some poorly soluble sequences need a dilute acetic acid or a small volume of an organic co-solvent to dissolve, and a co-solvent carries its own consequences for any downstream assay.
The arithmetic is simple and worth writing on the vial. A 10 mg vial taken up in 2 mL of diluent gives a concentration of 5 mg/mL; the same vial in 1 mL gives 10 mg/mL. That calculation is the only numeric exercise this site performs, and it stops there, because concentration is a property of a solution and nothing further follows from it.
At low concentrations, adsorption to glass and plastic removes a measurable fraction of the peptide from solution. Low-binding tubes help; so does a carrier protein where the assay tolerates one.
Bacteriostatic water is supplied here as Bacteriostatic Water. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. Nothing here is medical, dosing, or therapeutic guidance.
What a real stability claim would require
This is where the honest answer is uncomfortable.
A shelf life is not an opinion. It is the output of a stability programme: the material held at defined temperatures and humidities, sampled on a schedule, and analysed by methods that can detect each degradation route, with the acceptance criteria fixed in advance. The International Council for Harmonisation publishes the guidelines that define how such a study is designed and what accelerated conditions may be extrapolated from.
Research-chemical suppliers do not run those programmes, and neither does this one. What exists is a certificate for a lot at a point in time, plus general knowledge of peptide chemistry. That supports a storage recommendation. It does not support a stated expiry, and this site states none — no beyond-use date, no "stable for N months once reconstituted". Anyone who needs that figure for a particular compound has to generate it, which is itself a legitimate research question and a well-defined one.
Practical handling from receipt onward is in handling research peptides in the laboratory.
Common questions
My cake is cracked, shrunken, or stuck to the side of the vial. Is the material bad? Not necessarily. Cake appearance reflects the drying cycle and what happened in transit, and a collapsed or displaced cake is cosmetically alarming far more often than it is chemically meaningful. What would concern me is a cake that has visibly liquefied or discoloured, or a vial whose seal is compromised, because both point to moisture ingress.
Does a peptide expire? It degrades continuously, at a rate set by its sequence and its conditions. "Expiry" is a regulatory determination from a stability study, and for research material there is no such study, so there is no honest expiry date to publish.
Why −20 °C rather than −80 °C? For most lyophilised peptides, −20 °C in a sealed, desiccated state is well below the mobility threshold where significant chemistry proceeds, so colder buys little. −80 °C is worth it for long archival storage and for solutions.
Is it better to store the whole vial or to aliquot? Aliquot, if you will return to the material more than once. Each thaw, each opening and each withdrawal is a stress and an opportunity for contamination, and single-use aliquots remove all three for every use after the first.
Selected Research References
- Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice. Pharmaceutical Research. 1997;14(8):969-975. pubmed.ncbi.nlm.nih.gov/9279875
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of Protein Pharmaceuticals: An Update. Pharmaceutical Research. 2010;27(4):544-575. pubmed.ncbi.nlm.nih.gov/20143256
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.